BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-105@pharmaconomics
DTSTAMP:20260707T021158Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:GENE Phase 2 — REGN5668
DESCRIPTION:Phase 2 trial results for REGN5668 in Ovarian Cancer are due Mar 25\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT04590326\n\nTrack it: https://pharmaconomics.com/e/105
URL:https://pharmaconomics.com/e/105
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GENE catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR